Travel & Tourism Industry release:
NEW YORK, Feb. 13, 2018 /PRNewswire/ — WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on PTLA, PLX, RDUS, and RGLS which can be accessed for free by signing up to www.wallstequities.com/registration. Research reports have been issued by WallStEquities.com on Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Protalix BioTherapeutics Inc. (NYSE AMER: PLX), Radius Health Inc. (NASDAQ: RDUS), and Regulus Therapeutics Inc. (NASDAQ: RGLS). Companies in the Biotechnology space are engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct R&D. All you have to do is sign up today for this free limited time offer by clicking the link below.
On Monday, shares in South San Francisco, California headquartered Portola Pharmaceuticals Inc. recorded a trading volume of 714,014 shares. The stock ended at $46.70, rising 5.16% from the last trading session. The Company’s shares have gained 60.70% in the last twelve months. The stock is trading below its 50-day moving average by 7.11%. Furthermore, shares of Portola Pharma, which develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation, have a Relative Strength Index (RSI) of 43.32. Get the full research report on PTLA for free by clicking below at:
Karmiel, Israel-based Protalix BioTherapeutics Inc.’s stock finished yesterday’s session 4.80% higher at $0.66. A total volume of 412,713 shares was traded. The stock is trading below its 50-day moving average by 1.90%. Furthermore, shares of Protalix BioTherapeutics, which focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally, have an RSI of 47.19. PLX’s complimentary research coverage is a few simple steps away at: www.wallstequities.com/registration/?symbol=PLX
At the close of trading on Monday, shares in Waltham, Massachusetts headquartered Radius Health Inc. saw a rise of 3.58%, ending the day at $36.42. The stock recorded a trading volume of 564,497 shares. The Company’s shares have advanced 28.24% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 9.28% and 0.61%, respectively. Moreover, shares of Radius Health, which develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the US, have an RSI of 52.55.
On January 29th, 2018, research firm Morgan Stanley initiated an ‘Overweight’ rating on the Company’s stock, with a target price of $57 per share. Register for your free research report on RDUS at: www.wallstequities.com/registration/?symbol=RDUS
San Diego, California headquartered Regulus Therapeutics Inc.’s shares ended the day 4.50% higher at $1.16 with a total trading volume of 209,190 shares. The stock has gained 21.21% in the previous three months. The Company’s shares are trading above their 50-day and 200-day moving averages by 4.94% and 1.23%, respectively. Additionally, shares of Regulus Therapeutics, which focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the US, have an RSI of 48.60. Wall St. Equities’ downloadable research report on RGLS available at: www.wallstequities.com/registration/?symbol=RGLS
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-biotech-stocks—-portola-pharma-protalix-biotherapeutics-radius-health-and-regulus-therapeutics-300597735.html
SOURCE Wall St. Equities
Click here to read the full release with contact information on PR Newswire. Some releases are not in English.
To post and circulate your own press release on FIR and the eTN Network please click here
Comments are closed here.